BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Frontage Laboratories Begins Early Phase Clinical Program for Hisun Pharma


4/4/2012 11:17:11 AM

April 04, 2012 -- Frontage, the global contract research organization, today announced that it has successfully filed an Investigational New Drug (IND) application to launch a U.S. clinical program on behalf of Zhejiang Hisun Pharmaceutical Co., Ltd.

The IND enables Hisun to initiate an early phase clinical study for HS-25, an innovative cholesterol-lowering compound to treat the onset of hypercholesterolemia and nephrotic hyperlipidemia.

Unlike other statins, HS-25 inhibits intestinal cholesterol absorption and promotes biliary cholesterol excretion thus lowering total cholesterol and low density lipoprotein (LDL) to improve the body's cardiovascular function.

In addition to the U.S. filing, HS-25 has been submitted for Chinese and global protection under the Patent Cooperation Treaty. If ultimately successful, HS-25 will join a class of compounds that includes the number one cholesterol lowering drug, Lipitor, which generated global revenue of $9.6 billion last year for Pfizer.

As the U.S. regulatory agent for Hisun, Frontage supported the HS-25 IND filing with drug development and regulatory consulting services, including CMC and pharmaceutical toxicology, plus the clinical development plan and protocols. In addition, Frontage provided communications with the FDA ranging from the pre-IND meeting through the IND filing and post-IND discussions. Frontage will also conduct the Phase I trial and other clinical pharmacology studies for HS-25 at its U.S. clinical center.

About Frontage

Frontage Laboratories, Inc. is a global contract research, development and manufacturing organization, offering a full range of pharmaceutical R&D services. Frontage operates in the US and China, using one seamless GXP platform. Frontage runs three Phase 1 Clinical units, a 88-bed Phase 1 Unit in Hackensack, NJ, a 120-bed Phase 1 Unit in Zhengzhou, Henan Province China, and a-80 bed Phase 1 Unit in Changchun, Jiling Province China. Frontage has an AALAC certified preclinical animal facility in Pennsylvania, where it also maintains bioanalytical and CMC facilities. In Shanghai and Beijing, China, the company also operates bioanalytical and CMC facilities. As a rapidly expanding CRO with ten years of success providing high-quality GXP services, Frontage has established an international standard in pharmaceutical product research, development, quality and management systems.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES